Adicet Bio
NASDAQ: ACETMenlo Park, US · Founded 2014 · Delaware corporation · 7 known investors
Find your way into Adicet Bio
277 people in our graph share verified history with the Adicet Bio team — schools, employers, funds. One of them is your warm intro.
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer. The company works on off-the-shelf immune cell therapies based on gamma delta 1 CAR T cell technology.
Founders & leadership
Adicet Bio was founded in 2014 by Aya Jakobovits.

Board



Investors · 7
Reported raises · per SEC filings
Form D private placements$156.8M disclosed across 4 rounds · 2015–2019
▶$80MraisedOct 2019 · 18 investors · BiotechnologyRule 506(b)
- Erez ChimovitsDirector
- Francesco GaliniExecutive Officer
- Carrie KrehlikExecutive Officer
- Stewart AbbotExecutive Officer
- Carl GordonDirector
- Michal SilverbergDirector
- Donald SantelExecutive Officer, Director
- Yair SchindelDirector
- Asish XavierDirector
- Aya JakobovitsDirector
- Offering amount
- $80M
- Amount sold
- $80M
- Sales commissions
- $2.5M
- Placement agents
- Beech Hill Securities, Inc., Beech Hill Securities, Inc., Beech Hill Securities, Inc.
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$25.4MraisedOct 2018 · 5 investors · BiotechnologyRule 506(b)
- Jonathan SilversteinDirector
- Aya JakobovitsDirector
- Donald SantelExecutive Officer, Director
- Brian HoganExecutive Officer
- Carl GordonDirector
- Carrie KrehlikExecutive Officer
- Anne AltmeyerExecutive Officer
- Florent GrosDirector
- Erez ChimovitsDirector
- Steward AbbotExecutive Officer
- Offering amount
- $43.3M
- Amount sold
- $25.4M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$11.3MraisedJan 2016 · 6 investors · BiotechnologyRule 506(b)
- Nathan HubbardExecutive Officer
- Aya JakobovitsExecutive Officer, Director
- Jonathan SilversteinDirector
- Carl GordonDirector
- Florent GrosDirector
- Erez ChimovitsDirector
- Offering amount
- $13.9M
- Amount sold
- $11.3M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 7
by search overlapCompanies competing with Adicet Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Adicet Bio do?
- Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer. The company works on off-the-shelf immune cell therapies based on gamma delta 1 CAR T cell technology.
- Who founded Adicet Bio?
- Adicet Bio was founded by Aya Jakobovits in 2014.
- Who are Adicet Bio's investors?
- Adicet Bio's investors include Foresite Capital, OrbiMed, Pontifax Venture Capital, Quan Capital, aMoon, Novartis Venture Fund, PureTech Health.
- How much funding has Adicet Bio raised?
- Adicet Bio has disclosed $156.8M raised across 4 rounds.
- Where is Adicet Bio headquartered?
- Adicet Bio is headquartered in Menlo Park, US.





